Volume 31, Number 3—March 2025
Synopsis
Candida auris Outbreak and Epidemiologic Response in Burn Intensive Care Unit, Illinois, USA, 2021–2023
Table
Characteristics of 28 Candida auris outbreak case-patients in BICU, Illinois, USA, 2021–2023*
| Characteristic | Value |
|---|---|
| Sex | |
| F | 13 (46) |
| M |
15 (54) |
| Average age, y (range) |
49 (16–81) |
| Admission diagnosis | |
| Burn | 18 (64) |
| Soft tissue infection not including burns | 9 (32) |
| COVID-19† |
1 (4) |
| C. auris culture source | |
| Axillary/inguinal screening culture‡ | 24 (86) |
| Clinical culture§ | 14 (50) |
| Blood | 8 (29) |
| Respiratory | 6 (21) |
| Wound | 8 (29) |
| Urine |
3 (11) |
| Co-infection with multidrug-resistant organism¶ |
13 (46) |
| Mean length of stay from admission to first positive C. auris culture, d (range) |
26 (7–83) |
| Recent hospitalization <1 month before hospitalization |
8 (29) |
| Medical devices used <1 week before positive C. auris culture | |
| Central venous catheter | 24 (86) |
| Ventilator | 18 (64) |
| Urinary catheter |
24 (86) |
| Ancillary medical services received <1 week before first positive C. auris culture | |
| Occupational therapy | 23 (82) |
| Physical therapy | 18 (64) |
| Speech therapy |
5 (18) |
| Mean length of stay in BICU, d (range) |
67 (6–442) |
| C. auris outcome | |
| Colonization | 14 (50) |
| Infection |
13 (46) |
| Discharge disposition | |
| Skilled nursing facility, acute rehab or other hospital | 17 (61) |
| Home | 5 (18) |
| Deceased | 6 (21) |
*Values are no. (%) except as indicated. BICU, burn intensive care unit. †Medical intensive care unit service patient on overflow to BICU. ‡Ten of the 24 patients with a positive axillary/inguinal screen also had C. auris identified from a clinical culture. §Of the clinical cultures, 4 patients had C. auris identified only in blood, 3 had C. auris only from wound infections, 1 had C. auris only from respiratory source, and the remaining 6 had C. auris identified in >1 clinical culture source. ¶A total of 13 patients were co-infected or co-colonized with 19 other multidrug-resistant organisms: 6 vancomycin-resistant enterococci, 5 extended-spectrum β-lactamase–producing organisms, 3 methicillin-resistant Staphylococcus aureus, 2 multidrug-resistant Pseudomonas aeruginosa (MDR-PA), 1 carbapenem-resistant Acinetobacter baumannii, 1 carbapenem-resistant Enterobacterales, 1 AmpC β-lactamase–producing organism.
1These first authors contributed equally to this article.
2These authors contributed equally to this article.